

**2023 ASTCT Virtual Fundamentals of HCT Training Course Disclosures**

Name of Individual	Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest appropriate to role(s) in the activity
Alison Carulli, PharmD, BCOP	Peer Reviewer	No relevant financial disclosures	NA	NA
Anna Hawkshead	ASTCT Staff	No relevant financial disclosures	NA	NA
Anthony Perissinotti, PharmD, BCOP	Peer Reviewer	1. Abbvie, Pfizer, Rigel Pharmaceuticals, Sanofi Aventis, Servier	1. Non-CE Consulting	<p>The following financial relationships have been mitigated by:</p> <ul style="list-style-type: none"> <li>▪ Pfizer ended in September 2022</li> <li>▪ Rigel Pharmaceuticals ended in August 2022.</li> </ul> <p>All final review decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Chair.</p>
Arpita Ghandi, PharmD, BCOP	Faculty, Peer Reviewer	No relevant financial disclosures	NA	NA
Benjamin Andrick, PharmD, BCOP	Peer Reviewer, Planning Committee	No relevant financial disclosures	NA	NA
Breana Goscicki, PharmD, BCPPS	Peer Reviewer			
Cameron Ninos, PharmD, BCOP	Peer Reviewer	1. Dedham Group, Aptitude Heath	1. Non-CE Consulting	All final review decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Chair.
Craig Freyer, PharmD	Faculty, Planning Committee	1. Astellas	1. Non-CE Speakers Bureau	All final review decisions concerning content, learning objectives, and evaluation questions were

				made by the non-conflicted Planning Committee Chair.
Danielle Cenin, PharmD, BCOP	Peer Reviewer	No relevant financial disclosures	NA	NA
Denae Bechman, PharmD, BCOP	Peer Reviewer	No relevant financial disclosures	NA	NA
Elizabeth DiMaggio, PharmD, BCOP	Planning Committee	No relevant financial disclosures	NA	NA
Erika Waas, PharmD	Peer Reviewer	1. Omeros, Inc	1. Non-CE Speakers Bureau	All final review decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Chair.
Frank Oley Jr, PharmD, MBA, BCOP	Planning Committee	No relevant financial disclosures	NA	NA
Frank Tverdek, Pharm D	Peer Reviewer	No relevant financial disclosures	NA	NA
Gianni Scappatici, PharmD	Peer Reviewer	No relevant financial disclosures	NA	NA
Graham Klink, PharmD	Planning Committee	No relevant financial disclosures	NA	NA
Haedyn Smith	ASTCT Staff	No relevant financial disclosures	NA	NA
Hanna Bailey, PharmD, BCOP	Peer Reviewer	No relevant financial disclosures	NA	NA
Heather Tarbox, MPH	TFF Staff	No relevant financial disclosures	NA	NA
Hemalatha Rangarajan, MD	Faculty	No relevant financial disclosures	NA	NA
Ila Saunders, PharmD, BCOP	Faculty	1. EUSA Pharma, LLC; Merck, LLC	1. Non-CE Consulting	The following financial relationships have been mitigated by: <ul style="list-style-type: none"> <li>▪ EUSA Pharma, LLC ended in June 2021</li> <li>▪ Merck, LLC ended in June 2022.</li> </ul> Content was reviewed by a peer reviewer and non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based

				on scientific evidence and/or clinical reasoning.
James Shaw, PharmD, BCPS, BCOP	Peer Reviewer	No relevant financial disclosures	NA	NA
Janet Laquet, PharmD, BCPS, BCOP	Planning Committee	No relevant financial disclosures	NA	NA
Jasleen Chahal, PhD	TFF Staff	No relevant financial disclosures	NA	NA
Jason Ernstberger, PharmD	Faculty	1. Seattle Genetics		The following financial relationships have been mitigated by: <ul style="list-style-type: none"> <li>▪ Seattle Genetics ended in September 2021</li> </ul> Content was reviewed by a peer reviewer and non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Jason Yeh, PharmD, BCOP	Faculty, Planning Committee	1. Omeros	1. Non-CE Consulting	Content was reviewed by a peer reviewer and non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.  All final review and planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Chair.
Jennifer Collins, PharmD, BCOP	Faculty	No relevant financial disclosures	NA	NA
Julie Guglielmo, PharmD, BCOP	Peer Reviewer	No relevant financial disclosures	NA	NA

Justin Arnall, PharmD, BCOP	Peer Reviewer	1. CTI Biopharma, HEMA Biologics  2. Novo Nordisk	1. Non-CE Consulting (Advisory Board)  2. Non-CE Speakers Bureau	The following financial relationships have been mitigated by: <ul style="list-style-type: none"> <li>▪ CTI Biopharma ended in April 2022</li> <li>▪ HEMA ended in October 2022</li> <li>▪ Novo Nordisk ended in May 2022</li> </ul> All final review decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Chair.
Kathy Hogan Edwards, PharmD	Peer Reviewer	1. Omeros	1. Non-CE Consulting	All final review decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Chair.
Katie Gatwood, PharmD, BCOP	Faculty	1. Jazz Pharmaceuticals, Kite Pharma, Sanofi  2. AstraZeneca	1. Non-CE Consulting  2. Contract Research	Content was reviewed by a peer reviewer and non- conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Kendall Shultes, PharmD, BCOP	Planning Committee	1. Projects in Knowledge, Oncology Times	1. Non-CE Consulting	All final review and planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Chair.
Kristina Nelson, PharmD	Peer Reviewer	No relevant financial disclosures	NA	NA
Lauren Curry, PharmD	Peer Reviewer	No relevant financial disclosures	NA	NA
Lauren Ice, PharmD, BCOP	Planning Committee Chair	No relevant financial disclosures	NA	NA

LeAnne Kennedy, PharmD, BCOP, CPP, FHOPA	Faculty	No relevant financial disclosures	1. NA	NA
Maggie Nelson, PharmD, BCOP	Planning Committee	No relevant financial disclosures	NA	NA
Marco Ruiz, MD, MPH	Planning Committee, Peer Reviewer	No relevant financial disclosures	NA	NA
Molly Gallogly, MD, PhD	Peer Reviewer	No relevant financial disclosures	NA	NA
Nicole Soriano, PharmD	Planning Committee	No relevant financial disclosures	NA	NA
Rebecca Gonzalez, PharmD, BCOP	Faculty	No relevant financial disclosures	NA	NA
Rebecca Meyers, PharmD, BCOP	Planning Committee	No relevant financial disclosures	NA	NA
Savannah Gulley, PharmD, BCPPS	Peer Reviewer	No relevant financial disclosures	NA	NA
Susan Long, PharmD	Faculty, Planning Committee Chair- Elect	No relevant financial disclosures	NA	NA
Suzanne Gettys, PharmD, BCOP	Planning Committee	No relevant financial disclosures	NA	NA
Susan Prockop, MD	Faculty	1. ADMA, CellEvolve, Regeneron, Smart Immune	1. Non-CE Consulting	The following financial relationships have been mitigated by: <ul style="list-style-type: none"> <li>▪ ADMA ended in October 2022</li> <li>▪ Regeneron ended in September 2022</li> </ul> Content was reviewed by a peer reviewer and non-conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Taiga Nishihori, MD	Faculty	1. Medexus	1. Advisory Board	Content was reviewed by a peer reviewer and non-

				conflicted member of the planning committee to ensure that it is not commercially biased, was fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Tatjana Grgic, PharmD, BCOP, CPP	Peer Reviewer	No relevant financial disclosures	NA	NA
Terri Lynn Shigle, PharmD, BCPS, BCOP	Peer Reviewer	1. Takeda	1. Non-CE Consulting	The following financial relationships have been mitigated by: <ul style="list-style-type: none"> <li>▪ Takeda ended in December 2021</li> </ul> All final review decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Chair.
Timothy George, PharmD, BCOP	Peer Reviewer	1. Contrafect, CTI Biopharma, Gilead, Inari Medical, Myovant Sciences, Syros Pharmaceuticals, Valneva	1. Stock ownership of publicly held commercial entities	The following financial relationships have been mitigated by: <ul style="list-style-type: none"> <li>▪ Contrafect ended in March 2021</li> <li>▪ CTI Biopharma ended in March 2022</li> <li>▪ Gilead and Myovant Sciences ended in January 2021</li> <li>▪ Inari Medical ended in August 2021</li> </ul> All final review decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Chair.